Recommendations for the management of tyrosinaemia type 1

被引：142

作者：

de Laet, Corinne ^{[1
]}

Dionisi-Vici, Carlo ^{[2
]}

Leonard, James V. ^{[3
]}

McKiernan, Patrick ^{[4
]}

Mitchell, Grant ^{[5
]}

Monti, Lidia ^{[6
]}

de Baulny, Helene Ogier ^{[7
]}

Pintos-Morell, Guillem ^{[8
]}

Spiekerkoetter, Ute ^{[9
]}

机构：

[1] Univ Childrens Hosp Queen Fabiola, Dept Pediat, Nutr & Metab Unit, Brussels, Belgium

[2] Bambino Gesu Childrens Hosp IRCCS, Dept Pediat Med, Div Metab, Rome, Italy

[3] UCL Inst Child Hlth, London WC1N 1EH, England

[4] Birmingham Childrens Hosp, Liver Unit, Birmingham B4 6NH, W Midlands, England

[5] CHU St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada

[6] Bambino Gesu Childrens Hosp IRCCS, Dept Radiol, Unit Hepatobiliary Imaging, Rome, Italy

[7] Hop Robert Debre, Reference Ctr Inherited Metab Dis, F-75019 Paris, France

[8] Badalona Univ Autonoma Barcelona, Univ Hosp Germans Trias & Pujol, Sect Paediat Nephrol Genet & Metab, Dept Paediat, Catalonia, Spain

[9] Univ Childrens Hosp, Dept Pediat & Adolescent Med, D-79106 Freiburg, Germany

来源：

ORPHANET JOURNAL OF RARE DISEASES | 2013年 / 8卷

关键词：

Hepatorenal tyrosinaemia; Fumarylacetoacetase; Succinylacetone; Nitisinone; Cirrhosis; Acute live failure; Hepatocellular carcinoma; Low tyrosine diet; LIVER LESION DETECTION; HEREDITARY TYROSINEMIA; NTBC TREATMENT; NITISINONE;

D O I：

10.1186/1750-1172-8-8

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies. The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.

引用

页数：9

共 43 条

[1] Cardiomyopathy in tyrosinaemia type I is common but usually benign
Arora, N
Stumper, O
Wright, J
Kelly, DA
McKiernan, PJ
[J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 (01) : 54 - 57
[2] Hyperinsulinism in tyrosinaemia type I
Baumann, U
Preece, MA
Green, A
Kelly, DA
McKiernan, PJ
[J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 (02) : 131 - 135
[3] Lectin-reactive α-fetoprotein in patients with tyrosinemia type I and hepatocellular carcinoma
Baumann, Ulrich
Duhme, Valeska
Auth, Marcus K. H.
McKiernan, Patrick J.
Holme, Elisabeth
[J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2006, 43 (01) : 77 - 82
[4] Chakarapani A., 2012, Inborn Metabolic Diseases, P275
[5] Improved focal liver lesion detection:: comparison of single-shot diffusion-weighted echoplanar and single-shot T2 weighted turbo spin echo techniques
Coenegrachts, K.
Delanote, J.
Ter Beek, L.
Haspeslagh, M.
Bipat, S.
Stoker, J.
Van Kerkhove, F.
Steyaert, L.
Rigauts, H.
Casselman, J. W.
[J]. BRITISH JOURNAL OF RADIOLOGY, 2007, 80 (955) : 524 - 531
[6] Couce ML, 2010, AN PEDIAT BARC, V73
[7] Crone J, 2003, ACTA PAEDIATR, V92, P625
[8] Tyrosinemia type I: long-term outcome in a patient treated with doses of NTBC lower than recommended
D'Eufemia, Patrizia
Celli, Mauro
Tetti, Martina
Finocchiaro, Roberto
[J]. EUROPEAN JOURNAL OF PEDIATRICS, 2011, 170 (06) : 819 - 819
[9] Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned?
Daly, A.
Gokmen-Ozel, H.
MacDonald, A.
Preece, M. A.
Davies, P.
Chakrapani, A.
McKiernan, P.
[J]. JOURNAL OF HUMAN NUTRITION AND DIETETICS, 2012, 25 (02) : 111 - 116
[10] Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1
De Laet, Corinne
Munoz, Vanessa Terrones
Jaeken, Jaak
Francois, Baudouin
Carton, Dietbrandt
Sokal, Etienne M.
Dan, Bernard
Goyens, Philippe J.
[J]. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2011, 53 (10) : 962 - 964

← 1 2 3 4 5 →